3,6-dihydro-3,5-dimethyl-6-(4-methoxyphenyl)-2H-1,2-oxazine hydrochloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3,6-dihydro-3,5-dimethyl-6-(4-methoxyphenyl)-2H-1,2-oxazine hydrochloride
• 英文别名: 6-(4-methoxyphenyl)-3,5-dimethyl-3,6-dihydro-2H-oxazine;hydrochloride
• 化学式: C₁₃H₁₇NO₂*ClH
• 分子量: 255.744
• InChiKey: APOIIRTXPMVKIF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.03
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  30.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3,6-dihydro-3,5-dimethyl-6-(4-methoxyphenyl)-2H-1,2-oxazine hydrochloride 在 palladium on activated charcoal 氢气 、 三乙胺 作用下， 以 乙酸乙酯 、 苯 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 3.0h， 生成 3,5-dimethyl-6-(4-methoxyphenyl)-N-(3,4,5-trimethoxybenzoyl)tetrahydro-1,2-oxazine
  参考文献：
  名称：

  The Synthesis and Spectral Properties of N-(3,4,5-Trimethoxybenzoyl)-3,6-dihydro-1,2-oxazines and N-(3,4,5-Trimethoxybenzoyl)tetrahydro-1,2-oxaziens

  摘要：

  In an attempt to develop neurosedatives of enhanced pharmacological activity and lower side-effect toxicity than those currently available, a series of novel 3,4,5-trimethoxybenzamides derived from either 3,6-dihydro-1,2-oxazine or tetrahydro-1,2-oxazine has been synthesized and fully characterized spectroscopically.

  DOI：

  10.3987/com-91-5834

文献信息

• Use of n-substituted (3,6-dihydro)-2h-1,2-oxazine derivatives as selective mglur1 antagonists
  申请人：Eli Lilly and Company

  公开号：US06482824B1

  公开（公告）日：2002-11-19

  Use of a compound of formula (I) in which, R1, R2 and R3 are independently hydrogen, (C1-C6)alkyl, (C2-C6)alkenyl, C3-C10)cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted aryl(C1-C6)alkyl, unsubstituted or substituted aryl(C2-C6)alkenyl, halo, carboxy, (C1-C6)alkoxycarbonyl or —(CH2)m—OH wherein m is 1, 2 or 3; - - - indicates a single or a double bond; X and each independently hydrogen, or X and Y together represent a bridge of the formula —CH2)m—, where n is 1 or 2; A1 and A2 are each independently an unsubstituted or substituted aryl; Z is —CO—, —SO2— or —CH2; provided that, when Z is —CO—, A1 is not 3,4,5-trimethoxyphenyl; or a pharmaceutically-acceptable salt or ester thereof, for the manufacture of a medicament for the treatment of a condition indicating the administration of a selective mGluR1 antagonist.

  使用式(I)中的化合物，其中R1、R2和R3分别独立地为氢、(C1-C6)烷基、(C2-C6)烯基、(C3-C10)环烷基、未取代或取代的芳基、未取代或取代的芳基(C1-C6)烷基、未取代或取代的芳基(C2-C6)烯基、卤素、羧基、(C1-C6)烷氧羰基或—(CH2)m—OH，其中m为1、2或3；- - -表示单键或双键；X和每个独立地为氢，或者X和Y一起表示式—CH2)m—的桥，其中n为1或2；A1和A2各自独立地为未取代或取代的芳基；Z为—CO—、—SO2—或—CH2—；但是当Z为—CO—时，A1不是3,4,5-三甲氧基苯基；或其药学上可接受的盐或酯，用于制造治疗需要使用选择性mGluR1拮抗剂的疾病的药物。
• US6482824B1
  申请人：——

  公开号：US6482824B1

  公开（公告）日：2002-11-19
• The Synthesis and Spectral Properties of N-(3,4,5-Trimethoxybenzoyl)-3,6-dihydro-1,2-oxazines and N-(3,4,5-Trimethoxybenzoyl)tetrahydro-1,2-oxaziens
  作者：Henryk Labaziewicz、Bob A. Howell、Karl R. Lindfors、Rodney C. Mason

  DOI：10.3987/com-91-5834

  日期：——

  In an attempt to develop neurosedatives of enhanced pharmacological activity and lower side-effect toxicity than those currently available, a series of novel 3,4,5-trimethoxybenzamides derived from either 3,6-dihydro-1,2-oxazine or tetrahydro-1,2-oxazine has been synthesized and fully characterized spectroscopically.